MANE - Latest News

Veradermics, Incorporated (MANE), operates in Healthcare / Biotechnology, trades on NYSE.

Market capitalization stands near $5.17B. Beta to the broader market is 0.77.

The article list below shows the most recent MANE headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent MANE Headlines

Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months

benzinga.com - Jul 15, 2026

Veradermics Incorporated (NYSE:MANE) on Wednesday released topline results from an open-label Phase 2 trial evaluating its experimental VDPHL01 in wom

Veradermics, Incorporated (MANE) Discusses Positive Female Results From Phase II Study of VDPHL01 for Pattern Hair Loss Transcript

seekingalpha.com - Jul 15, 2026

Veradermics, Incorporated (MANE) Discusses Positive Female Results From Phase II Study of VDPHL01 for Pattern Hair Loss Transcript

Veradermics Hair Loss Pill Shows Strong Phase II Signal in Women

marketbeat.com - Jul 15, 2026

Veradermics NYSE: MANE said results from the female arms of Study 207, a phase II open-label trial of VDPHL01 for mild to moderate pattern hair loss,

Veradermics' Oral VDPHL01 Delivers Positive Study ‘207' Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306' Readout

businesswire.com - Jul 15, 2026

NEW HAVEN, Conn. --(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on d

Veradermics to Hold Conference Call to Discuss Study ‘207' Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss

businesswire.com - Jul 14, 2026

NEW HAVEN, Conn. --(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on d

How News Affects MANE Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track MANE's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked MANE news questions

What is the latest MANE news headline?

The most recent MANE headline (Jul 15, 2026) is "Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the MANE news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What MANE news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual MANE options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.